April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative

Tareq Abadl/LinkedIn

Feb 18, 2026, 16:26

Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative

Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:

“CMV and Transfusion — Leukoreduction vs CMV-Seronegative

Cytomegalovirus (CMV) can be transmitted through blood components, but modern transfusion practice has reduced this risk dramatically.

For most at-risk patients, pre-storage leukoreduced (‘CMV-safe’) components are considered an effective alternative to routinely using CMV-seronegative units — with a few important exceptions.

What Major Authorities Say?

Organizations such as the AABB, the Centers for Disease Control and Prevention (CDC), and national blood services like Canadian Blood Services recognize that:

Pre-storage leukoreduction significantly reduces transfusion-transmitted CMV (TT-CMV).
Many programs consider leukoreduced (CMV-safe) and CMV-seronegative components clinically equivalent for most indications.

Important Exceptions

Maximal prevention is still recommended in certain high-risk settings:

Intrauterine transfusion (IUT)
Some extremely low-birthweight neonates

Selected transplant or severely immunocompromised patients (based on local policy)

In these cases, request CMV-seronegative units in addition to leukoreduction.
Always follow your institution’s policy and consult neonatology/transplant teams when needed.

Practical Blood Bank Guidance

Default practice:
Provide pre-storage leukoreduced components for routine transfusion.

For listed exceptions:
Request CMV-seronegative units plus leukoreduction.
Document the clinical indication clearly in the order.

System optimization:

Tag ‘CMV-safe’ components automatically in the LIS.

Add a required checkbox for ‘CMV-seronegative requested’ with documented reason.

Audit compliance and outcomes periodically.

Why Leukoreduction Works?

CMV resides mainly in white blood cells.
Leukoreduction removes the majority of this cellular reservoir, dramatically lowering TT-CMV risk.

That’s why many blood services shifted away from maintaining large universal seronegative inventories — it simplifies logistics while remaining protective for most patients.

Summary